Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lennernäs H[au]:

Search results

Items: 1 to 50 of 211

1.

Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches.

Dahlgren D, Lennernäs H.

Pharmaceutics. 2019 Aug 13;11(8). pii: E411. doi: 10.3390/pharmaceutics11080411. Review.

2.

Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile.

Dubbelboer IR, Pavlovic N, Heindryckx F, Sjögren E, Lennernäs H.

Cancers (Basel). 2019 Jul 20;11(7). pii: E1024. doi: 10.3390/cancers11071024.

3.

Effects of absorption-modifying excipients on jejunal drug absorption in simulated fasted and fed luminal conditions.

Roos C, Dahlgren D, Sjögren E, Sjöblom M, Hedeland M, Lennernäs H.

Eur J Pharm Biopharm. 2019 Sep;142:387-395. doi: 10.1016/j.ejpb.2019.07.012. Epub 2019 Jul 12.

PMID:
31306752
4.

Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations.

Dahlgren D, Sjöblom M, Lennernäs H.

Eur J Pharm Biopharm. 2019 Sep;142:411-420. doi: 10.1016/j.ejpb.2019.07.013. Epub 2019 Jul 12. Review.

PMID:
31306749
5.

Rat intestinal drug permeability: A status report and summary of repeated determinations.

Dubbelboer IR, Dahlgren D, Sjögren E, Lennernäs H.

Eur J Pharm Biopharm. 2019 Sep;142:364-376. doi: 10.1016/j.ejpb.2019.07.005. Epub 2019 Jul 5.

PMID:
31283980
6.

Evaluation of drug permeability calculation based on luminal disappearance and plasma appearance in the rat single-pass intestinal perfusion model.

Dahlgren D, Roos C, Peters K, Lundqvist A, Tannergren C, Sjögren E, Sjöblom M, Lennernäs H.

Eur J Pharm Biopharm. 2019 Sep;142:31-37. doi: 10.1016/j.ejpb.2019.06.011. Epub 2019 Jun 12.

PMID:
31201856
7.

Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model.

Eriksson J, Thörn H, Sjögren E, Holmstén L, Rubin K, Lennernäs H.

Mol Pharm. 2019 Jul 1;16(7):3053-3064. doi: 10.1021/acs.molpharmaceut.9b00289. Epub 2019 Jun 11.

PMID:
31136181
8.

Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited.

Al-Saffar A, Lennernäs H, Hellström PM.

Neurogastroenterol Motil. 2019 May 2:e13617. doi: 10.1111/nmo.13617. [Epub ahead of print] Review.

PMID:
31050085
9.

Single bead investigation of a clinical drug delivery system - A novel release mechanism.

Ahnfelt E, Gernandt J, Al-Tikriti Y, Sjögren E, Lennernäs H, Hansson P.

J Control Release. 2018 Dec 28;292:235-247. doi: 10.1016/j.jconrel.2018.11.011. Epub 2018 Nov 10.

10.

Mechanistic modelling of intestinal drug absorption - The in vivo effects of nanoparticles, hydrodynamics, and colloidal structures.

Roos C, Westergren J, Dahlgren D, Lennernäs H, Sjögren E.

Eur J Pharm Biopharm. 2018 Dec;133:70-76. doi: 10.1016/j.ejpb.2018.10.006. Epub 2018 Oct 6.

PMID:
30300720
11.

Jejunal absorption of aprepitant from nanosuspensions: Role of particle size, prandial state and mucus layer.

Roos C, Dahlgren D, Sjögren E, Sjöblom M, Hedeland M, Lennernäs H.

Eur J Pharm Biopharm. 2018 Nov;132:222-230. doi: 10.1016/j.ejpb.2018.09.022. Epub 2018 Sep 25.

PMID:
30266667
12.

Time-dependent effects on small intestinal transport by absorption-modifying excipients.

Dahlgren D, Roos C, Lundqvist A, Tannergren C, Sjöblom M, Sjögren E, Lennernäs H.

Eur J Pharm Biopharm. 2018 Nov;132:19-28. doi: 10.1016/j.ejpb.2018.09.001. Epub 2018 Sep 1.

PMID:
30179738
13.

Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment.

Dubbelboer IR, Sjögren E, Lennernäs H.

AAPS J. 2018 Aug 30;20(6):96. doi: 10.1208/s12248-018-0251-4.

PMID:
30167825
14.

Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.

Prieto Garcia L, Janzén D, Kanebratt KP, Ericsson H, Lennernäs H, Lundahl A.

Drug Metab Dispos. 2018 Oct;46(10):1420-1433. doi: 10.1124/dmd.118.081364. Epub 2018 Aug 1.

PMID:
30068519
15.

Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport.

Dahlgren D, Roos C, Lundqvist A, Tannergren C, Sjöblom M, Sjögren E, Lennernäs H.

Int J Pharm. 2018 Oct 5;549(1-2):239-248. doi: 10.1016/j.ijpharm.2018.07.057. Epub 2018 Jul 26.

PMID:
30055302
16.

Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st Century BA/BE' project.

Hens B, Sinko PD, Job N, Dean M, Al-Gousous J, Salehi N, Ziff RM, Tsume Y, Bermejo M, Paixão P, Brasseur JG, Yu A, Talattof A, Benninghoff G, Langguth P, Lennernäs H, Hasler WL, Marciani L, Dickens J, Shedden K, Sun D, Amidon GE, Amidon GL.

Int J Pharm. 2018 Sep 5;548(1):120-127. doi: 10.1016/j.ijpharm.2018.06.050. Epub 2018 Jun 23. Review.

PMID:
29944899
17.

The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs.

Dahlgren D, Roos C, Johansson P, Tannergren C, Lundqvist A, Langguth P, Sjöblom M, Sjögren E, Lennernäs H.

Int J Pharm. 2018 Aug 25;547(1-2):158-168. doi: 10.1016/j.ijpharm.2018.05.029. Epub 2018 May 11.

PMID:
29758344
18.

Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis.

Eriksson J, Sjögren E, Thörn H, Rubin K, Bäckman P, Lennernäs H.

Eur J Pharm Biopharm. 2018 Mar;124:1-12. doi: 10.1016/j.ejpb.2017.11.013. Epub 2017 Nov 27.

PMID:
29191716
19.

Reply to "Comment on 'In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma'".

Dubbelboer IR, Lilienberg E, Karalli A, Axelsson R, Brismar TB, Ebeling Barbier C, Norén A, Duraj F, Hedeland M, Bondesson U, Sjögren E, Stål P, Nyman R, Lennernäs H.

Mol Pharm. 2018 Jan 2;15(1):336-340. doi: 10.1021/acs.molpharmaceut.7b00840. Epub 2017 Dec 1. No abstract available.

PMID:
29185767
20.

Regional Intestinal Permeability in Rats: A Comparison of Methods.

Roos C, Dahlgren D, Sjögren E, Tannergren C, Abrahamsson B, Lennernäs H.

Mol Pharm. 2017 Dec 4;14(12):4252-4261. doi: 10.1021/acs.molpharmaceut.7b00279. Epub 2017 Oct 5.

PMID:
28920690
21.

Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker 51Cr-EDTA.

Dahlgren D, Roos C, Lundqvist A, Tannergren C, Langguth P, Sjöblom M, Sjögren E, Lennernäs H.

Mol Pharm. 2017 Dec 4;14(12):4243-4251. doi: 10.1021/acs.molpharmaceut.7b00353. Epub 2017 Aug 8.

PMID:
28737406
22.

In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations.

Roos C, Dahlgren D, Berg S, Westergren J, Abrahamsson B, Tannergren C, Sjögren E, Lennernäs H.

Mol Pharm. 2017 Dec 4;14(12):4233-4242. doi: 10.1021/acs.molpharmaceut.7b00294. Epub 2017 Aug 10.

PMID:
28737398
23.

An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.

Tammela TL, Häggman M, Ladjevardi S, Taari K, Isotalo T, Lennernäs H, Weis J, von Below C, Wassberg C, Lennernäs B, Tolf A, Axén N, Gölander CG, Ahlström H.

J Urol. 2017 Dec;198(6):1333-1339. doi: 10.1016/j.juro.2017.07.072. Epub 2017 Jul 20.

PMID:
28736321
24.

In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.

Lennernäs H, Lindahl A, Van Peer A, Ollier C, Flanagan T, Lionberger R, Nordmark A, Yamashita S, Yu L, Amidon GL, Fischer V, Sjögren E, Zane P, McAllister M, Abrahamsson B.

Mol Pharm. 2017 Apr 3;14(4):1307-1314. doi: 10.1021/acs.molpharmaceut.6b00824. Epub 2017 Mar 1.

PMID:
28195732
25.

Computational fluid dynamics (CFD) studies of a miniaturized dissolution system.

Frenning G, Ahnfelt E, Sjögren E, Lennernäs H.

Int J Pharm. 2017 Apr 15;521(1-2):274-281. doi: 10.1016/j.ijpharm.2017.01.072. Epub 2017 Feb 9.

PMID:
28189856
26.

A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.

Dubbelboer IR, Lilienberg E, Sjögren E, Lennernäs H.

Mol Pharm. 2017 Mar 6;14(3):686-698. doi: 10.1021/acs.molpharmaceut.6b00974. Epub 2017 Feb 23.

PMID:
28182434
27.

In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma.

Lilienberg E, Dubbelboer IR, Karalli A, Axelsson R, Brismar TB, Ebeling Barbier C, Norén A, Duraj F, Hedeland M, Bondesson U, Sjögren E, Stål P, Nyman R, Lennernäs H.

Mol Pharm. 2017 Feb 6;14(2):448-458. doi: 10.1021/acs.molpharmaceut.6b00886. Epub 2017 Jan 5.

PMID:
27997198
28.

Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs.

Lilienberg E, Dubbelboer IR, Sjögren E, Lennernäs H.

J Pharm Pharmacol. 2017 Feb;69(2):135-142. doi: 10.1111/jphp.12665. Epub 2016 Nov 23.

PMID:
27882559
29.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:610-625. doi: 10.1016/j.ejps.2016.10.036. Epub 2016 Nov 2.

PMID:
27816631
30.

Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs.

Forner K, Roos C, Dahlgren D, Kesisoglou F, Konerding MA, Mazur J, Lennernäs H, Langguth P.

Drug Dev Ind Pharm. 2017 Feb;43(2):338-346. doi: 10.1080/03639045.2016.1251449. Epub 2016 Nov 6.

PMID:
27762631
31.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:626-642. doi: 10.1016/j.ejps.2016.09.037. Epub 2016 Sep 28.

PMID:
27693299
32.

IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.

Margolskee A, Darwich AS, Pepin X, Pathak SM, Bolger MB, Aarons L, Rostami-Hodjegan A, Angstenberger J, Graf F, Laplanche L, Müller T, Carlert S, Daga P, Murphy D, Tannergren C, Yasin M, Greschat-Schade S, Mück W, Muenster U, van der Mey D, Frank KJ, Lloyd R, Adriaenssen L, Bevernage J, De Zwart L, Swerts D, Tistaert C, Van Den Bergh A, Van Peer A, Beato S, Nguyen-Trung AT, Bennett J, McAllister M, Wong M, Zane P, Ollier C, Vicat P, Kolhmann M, Marker A, Brun P, Mazuir F, Beilles S, Venczel M, Boulenc X, Loos P, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:598-609. doi: 10.1016/j.ejps.2016.09.027. Epub 2016 Sep 23.

PMID:
27671970
33.

In Vitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System.

Ahnfelt E, Sjögren E, Hansson P, Lennernäs H.

J Pharm Sci. 2016 Nov;105(11):3387-3398. doi: 10.1016/j.xphs.2016.08.011. Epub 2016 Sep 20.

34.

Regional Intestinal Permeability of Three Model Drugs in Human.

Dahlgren D, Roos C, Lundqvist A, Abrahamsson B, Tannergren C, Hellström PM, Sjögren E, Lennernäs H.

Mol Pharm. 2016 Sep 6;13(9):3013-21. doi: 10.1021/acs.molpharmaceut.6b00514. Epub 2016 Aug 18.

PMID:
27504798
35.

Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms.

Dahlgren D, Roos C, Johansson P, Lundqvist A, Tannergren C, Abrahamsson B, Sjögren E, Lennernäs H.

Mol Pharm. 2016 Sep 6;13(9):3022-33. doi: 10.1021/acs.molpharmaceut.6b00515. Epub 2016 Aug 18.

PMID:
27500599
36.

Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study.

Johannsson G, Lennernäs H, Marelli C, Rockich K, Skrtic S.

Eur J Endocrinol. 2016 Jul;175(1):85-93. doi: 10.1530/EJE-15-1212. Epub 2016 Apr 29.

37.

Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.

Malm-Erjefält M, Ekblom M, Vouis J, Zdravkovic M, Lennernäs H.

Mol Pharm. 2015 Nov 2;12(11):4166-73. doi: 10.1021/acs.molpharmaceut.5b00278. Epub 2015 Oct 12.

PMID:
26426736
38.

Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption.

Olivares-Morales A, Lennernäs H, Aarons L, Rostami-Hodjegan A.

AAPS J. 2015 Sep;17(5):1177-92. doi: 10.1208/s12248-015-9758-0. Epub 2015 May 19.

39.

Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data.

Sjögren E, Dahlgren D, Roos C, Lennernäs H.

Mol Pharm. 2015 Jun 1;12(6):2026-39. doi: 10.1021/mp500834v. Epub 2015 May 6.

PMID:
25919764
40.

A miniaturized in vitro release method for investigating drug-release mechanisms.

Ahnfelt E, Sjögren E, Axén N, Lennernäs H.

Int J Pharm. 2015;486(1-2):339-49. doi: 10.1016/j.ijpharm.2015.03.076. Epub 2015 Apr 2.

41.

Direct In Vivo Human Intestinal Permeability (Peff ) Determined with Different Clinical Perfusion and Intubation Methods.

Dahlgren D, Roos C, Sjögren E, Lennernäs H.

J Pharm Sci. 2015 Sep;104(9):2702-26. doi: 10.1002/jps.24258. Epub 2014 Nov 19. Review.

PMID:
25410736
42.

The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.

Selen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, Martinez MN, Lennernäs H, Wigal TL, Swinney DC, Polli JE, Serajuddin ATM, Cook JA, Dressman JB.

J Pharm Sci. 2014 Nov;103(11):3377-3397. doi: 10.1002/jps.24162. Epub 2014 Sep 24. Review.

PMID:
25256402
43.

Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy.

Johannsson G, Falorni A, Skrtic S, Lennernäs H, Quinkler M, Monson JP, Stewart PM.

Clin Endocrinol (Oxf). 2015 Jan;82(1):2-11. doi: 10.1111/cen.12603. Epub 2014 Oct 10. Review.

PMID:
25187037
44.

Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model.

Sjögren E, Tammela TL, Lennernäs B, Taari K, Isotalo T, Malmsten LÅ, Axén N, Lennernäs H.

Mol Pharm. 2014 Sep 2;11(9):3097-111. doi: 10.1021/mp5002813. Epub 2014 Aug 7.

PMID:
25055161
45.

Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.

Nilsson AG, Marelli C, Fitts D, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Lennernäs H, Skrtic S, Johannsson G.

Eur J Endocrinol. 2014 Sep;171(3):369-77. doi: 10.1530/EJE-14-0327. Epub 2014 Jun 18.

46.

Theme issue 5th World Conference on Drug Absorption, Transport and Delivery.

Lennernäs H, Langguth P, Yamashita S, Crommelin DJ.

Eur J Pharm Sci. 2014 Sep 30;61:1. doi: 10.1016/j.ejps.2014.05.013. No abstract available.

PMID:
24929622
47.

Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems.

Dubbelboer IR, Lilienberg E, Ahnfelt E, Sjögren E, Axén N, Lennernäs H.

Ther Deliv. 2014 Apr;5(4):447-66. doi: 10.4155/tde.14.11. Review.

48.

Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments.

Johannsson G, Skrtic S, Lennernäs H, Quinkler M, Stewart PM.

Curr Med Res Opin. 2014 Sep;30(9):1833-47. doi: 10.1185/03007995.2014.925865. Epub 2014 Jun 9. Review.

PMID:
24849526
49.

Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition.

Smith D, Artursson P, Avdeef A, Di L, Ecker GF, Faller B, Houston JB, Kansy M, Kerns EH, Krämer SD, Lennernäs H, van de Waterbeemd H, Sugano K, Testa B.

Mol Pharm. 2014 Jun 2;11(6):1727-38. doi: 10.1021/mp400713v. Epub 2014 May 6. Review.

PMID:
24724562
50.

In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.

Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, Brouwers J, Flanagan T, Harwood M, Heinen C, Holm R, Juretschke HP, Kubbinga M, Lindahl A, Lukacova V, Münster U, Neuhoff S, Nguyen MA, Peer Av, Reppas C, Hodjegan AR, Tannergren C, Weitschies W, Wilson C, Zane P, Lennernäs H, Langguth P.

Eur J Pharm Sci. 2014 Jun 16;57:99-151. doi: 10.1016/j.ejps.2014.02.010. Epub 2014 Mar 15. Review.

PMID:
24637348

Supplemental Content

Loading ...
Support Center